



**Oramed Pharmaceuticals Inc.**  
**1185 Avenue of the Americas**  
**New York, NY 10036**  
**Phone: 1 844 9 ORAMED**  
**www.oramed.com**

## COMPANY OVERVIEW

- Breakthrough platform technology for oral delivery of drugs and vaccines presently available only via injection
- Pipeline currently focused on diabetes, with potential for a variety of additional treatment indications addressing multi-billion-dollar markets
- Recently announced positive results from oral insulin (ORMD-0801) pivotal Phase 2b study
- Preparing for Phase 3 discussions with US FDA
- Oramed's lead product, oral insulin, has potential to be the first commercial oral insulin
- Robust worldwide patent portfolio protection

## EQUITY OVERVIEW

(as of 6/5/20)

**Nasdaq/TASE:** ORMP

**Price:** ~\$3.47

**Market Cap:** \$80.76 M

**52 Week Range:** \$2.32-\$6.05

**Avg. Daily Volume (90 day):** 105 K

**Shares Outstanding:** 23.1 M

**Cash/Investments:** \$48.7 M (as of 3/2/20)

## ANALYST COVERAGE

- H.C. Wainwright & Co.
- Ladenburg Thalmann
- Aegis Capital
- Zacks

## BETTER WAY TO TREAT DIABETES

**1 in 11 adults  
on the planet has**

**1 healthcare  
in 8  
Is spent on diabetes**

**every  
6 SECONDS  
1 adult dies  
from diabetes  
4M deaths in 2017**

## INVESTMENT HIGHLIGHTS

### Breakthrough Platform Technology Delivers Injectable Drugs Orally

Oramed's unique Protein Oral Delivery (POD™) technology enables small proteins such as insulin to travel through the gastrointestinal tract and into the bloodstream. This method is more natural and should eliminate many of the negative side-effects of injection delivery. The oral administration of current injection-only therapies for conditions including diabetes should offer clear benefits including increased compliance and safety, fewer side effects and greater comfort for patients.

### Addressing \$70 Billion Market with Oral Formulations

Roughly \$70 billion worth of drugs and vaccines are currently delivered via injection. This includes the diabetes market where \$24 billion of insulin and \$6 billion of GLP-1 analogs were sold globally in 2017. The vaccine market size was approximately \$33.6 billion in 2017 and is expected to surpass \$103.6 billion by 2028.

### Oral Treatment has the Potential to Curb Progression of Type 2 Diabetes

ORMD-0801 has the potential to create a new paradigm in the treatment of type 2 diabetes by orally delivering insulin at an earlier stage of treatment. Earlier treatment can potentially slow disease progression and delay late-stage complications. Oramed successfully completed a 90-day HbA1c study of ORMD-0801, which met its primary endpoint achieving a statistically significant reduction of HbA1c. Oramed is now preparing for Phase 3 study discussions with the FDA, and is pursuing a Biologics License Application (BLA) regulatory pathway for ORMD-0801 which would grant a full 12 years of marketing exclusivity, if approved.

### Oral GLP-1 Analog to Stimulate Insulin Production in Type 2 Diabetes

Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. It is beneficial to type 2 diabetic patients by promoting weight loss and decreasing blood glucose. Oramed's ORMD-0901, an oral GLP-1 analog completed small clinical trials with encouraging results it is currently in the midst of a bioavailability study in the US.

## 2020 ANTICIPATED UPCOMING MILESTONES

ORMD-0801: Oral Insulin	<ul style="list-style-type: none"> <li>➤ Initiate Phase 3 in diabetes patients</li> <li>➤ Report data from Part 1 of NASH exploratory study</li> <li>➤ Initiate Part 2 of NASH exploratory study</li> </ul>
ORMD-0901: Oral GLP-1	<ul style="list-style-type: none"> <li>➤ Complete bioavailability study in diabetes patients</li> </ul>
Oral Leptin	<ul style="list-style-type: none"> <li>➤ Phase 1 initiation &amp; completion</li> </ul>